1. Nine-Month Trend of IgG Antibody Persistence and Associated Symptoms Post-SARS-CoV-2 Infection.
- Author
-
Lugo-Trampe, Angel, López-Cifuentes, Daniel, Mendoza-Pérez, Paúl, Tafurt-Cardona, Yaliana, Joo-Domínguez, Alejandra de Jesús, Rios-Ibarra, Clara Patricia, Espinoza-Ruiz, Marisol, Chang-Rueda, Consuelo, Rodriguez-Sanchez, Iram Pablo, Martinez-Fierro, Margarita L., Delgado-Enciso, Iván, and Trujillo-Murillo, Karina del Carmen
- Subjects
VIRAL antibodies ,RESEARCH funding ,POST-acute COVID-19 syndrome ,IMMUNOGLOBULINS ,SCIENTIFIC observation ,COVID-19 testing ,REVERSE transcriptase polymerase chain reaction ,CHI-squared test ,DESCRIPTIVE statistics ,LONGITUDINAL method ,ODDS ratio ,DATA analysis software ,CONFIDENCE intervals ,COVID-19 - Abstract
Between 2 and 8.5% of patients who recover from COVID-19 do not develop antibodies, and the durability of IgG antibodies is under scrutiny. Therefore, the presence and persistence of IgM and IgG antibodies were evaluated in a group of patients diagnosed with SARS-CoV-2 from May to August 2020. Out of 2199 suspected COVID-19 cases, 1264 were confirmed for SARS-CoV-2 by rRT-PCR; 328 consented to participate in the study, with 220 participants followed for 9 months, including 124 men (56%) and 96 women (44%). The primary symptoms were headache, dry cough, and fever. IgG antibodies developed in 95% of patients within 4 weeks post-diagnosis, and a second evaluation at 9 months showed that 72.7% still had detectable IgG antibodies. The presence of IgM in one individual (0.45%) suggested the possibility of reinfection. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF